Inflammatory peripheral neuropathies — Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and vasculitic neuropathies requiring immune-modulating therapy — represent clinically complex and commercially significant neuropathy treatment market segments, with the Peripheral Neuropathy Market reflecting the established and emerging treatment landscape for immune-mediated neuropathies.

CIDP treatment evolution — intravenous immunoglobulin, subcutaneous immunoglobulin (Hizentra, HyQvia), plasma exchange, and corticosteroids representing the established CIDP treatment options that complement each other and alternate based on individual response — creates a complex treatment landscape that new FcRn inhibitor approaches are disrupting.

Efgartigimod (Vyvgart) and nipocalimab — FcRn inhibitor antibodies reducing pathogenic IgG antibody levels including the autoantibodies causing CIDP — represent the novel mechanism entering the CIDP market based on the ADHERE trial demonstrating efgartigimod alfa/hyaluronidase superiority to placebo for CIDP relapse prevention. The FcRn inhibitor mechanism provides sustained IgG reduction that IVIg infusions cannot maintain between dosing intervals, offering potential for more stable CIDP control.

Rituximab for refractory CIDP and other inflammatory neuropathies — the anti-CD20 B cell depleting therapy used off-label for anti-MAG neuropathy, anti-CNTN1/CASPR1 neuropathy, and other antibody-mediated inflammatory neuropathies — represents the biological therapy that serves specific antibody-defined neuropathy subtypes. The identification of specific target antigens (contactin-1, caspr1, LGI4) in CIDP subgroups provides the precision medicine framework that rituximab and other targeted B cell therapies serve.

Do you think FcRn inhibitor treatments will significantly reduce IVIg dependency in CIDP management, changing the treatment market and potentially improving patient quality of life through more convenient administration?

FAQ

What is CIDP and how is it treated? Chronic inflammatory demyelinating polyneuropathy is an autoimmune peripheral neuropathy causing progressive weakness and sensory loss; first-line treatments include intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin, plasma exchange, and corticosteroids; FcRn inhibitors (efgartigimod, rozanolixizumab) represent a novel mechanism reducing IgG autoantibodies; rituximab serves refractory cases and specific antibody subtypes.

What are FcRn inhibitors for CIDP? FcRn (neonatal Fc receptor) inhibitors reduce serum IgG levels including pathogenic autoantibodies by blocking the FcRn recycling pathway that normally maintains IgG from lysosomal degradation; efgartigimod (Vyvgart, Argenx) received FDA approval for CIDP as efgartigimod alfa/hyaluronidase; the mechanism provides an alternative to IVIg by targeting the pathogenic antibody class broadly.

#PeripheralNeuropathy #CIDP #InflammatoryNeuropathy #FcRninhibitor #Efgartigimod #IVIGneuropathy